Metformin and Severe Post‐ COVID ‐19 Outcomes Among Individuals With Diabetes Mellitus
Main finding · All-cause mortality after COVID-19Result — go to the resultAdjusted risk ratio [aRR] 0.61 95% CI 0.51–0.73Authors' conclusion
These findings support the hypothesis that metformin prescription during acute COVID-19 may be associated with lower mortality among adults with diabetes.
Study context
- Population
- Individuals in the National Clinical Cohort Collaborative with Type 2 diabetes mellitus and COVID-19 who were prescribed metformin or a dipeptidyl peptidase-4 inhibitor (DPP4i) at least 30 days before the onset of acute COVID-19 between 1 October 2021, and 15 November 2023individuals with Type 2 diabetes and COVID-19
- Participants
- 53,332 individuals
- Exposure
- Individuals prescribed metformin versus DPP4i
- Outcome
- All-cause mortality after COVID-19
- Follow-up
- 12-month
Methodological detailsSuper Learner and targeted maximum likelihood estimation
- Super Learner and targeted maximum likelihood estimation
Main finding
As reported in the abstract
Adjusted risk ratio [aRR]
0.61
95% CI 0.51–0.73
METFORMINvs DPP4i
adjusted risk ratio [aRR] 0.61 (95% CI 0.51–0.73)
Observational data: associations, not effects.
Further findings
| Outcome | aRR (95% CI) | |
|---|---|---|
| Probable Long COVID (based on a model-derived phenotype) · 12-month | 0.87 (0.81–0.94) | |
| Long COVID diagnosis (ICD-10 U09.9) · 12-monthDid not detect a significant relationship | 0.90 (0.68–1.20) | |
| 0.512Adjusted relative risk (log scale) |
Original publication
Metformin and Severe Post‐ COVID ‐19 Outcomes Among Individuals With Diabetes Mellitus. Diabetes Obes Metab. Published 5 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →